Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 350

Welcome to Firstlinks Edition 350

We have reached a critical moment in the coronavirus fight, and this edition brings some heavy-hitting opinions from Warwick McKibbin, Christopher Joye and Rob Arnott, plus three other articles on implications. The next two weeks will deliver a major moment in history when President Donald Trump decides whether to ignore medical advice and lessons from other countries.

"Our country wasn't built to be shut down. America will again and soon be open for business. Very soon. A lot sooner than three or four months that somebody was suggesting."

Given what we know about how the virus spreads, removing restrictions on movements and isolation requirements will lead to a massive increase in infections and deaths.

There's no way to sugarcoat the impact on health and wealth, but we should remember that those who have lost the most money had the most to begin with. If it makes anyone feel better, Warren Buffett's Berkshire Hathaway's Top 15 listed holdings fell in value by $84 billion from US$242 billion to US$158 billion between the end of 2019 and 20 March 2020, a drop of 35%. Two of his stocks, General Motors and Wells Fargo, fell 50%.

It's more than a financial disaster for many. About 10% of working households in Australia have less than $90 in the bank, according to the Grattan Institute. Half have less than $7,000. We are about to see a million more Australians on welfare, thousands will lose their businesses, and Bill Evans of Westpac is forecasting an unemployment rate of 11.1% and a June quarter contraction of 3.5%. Most of us never expected to see queues of people around the block at Centrelink offices, a reminder of the Great Depression.

We can be sure that far more people will access the permitted $10,000 a year from their super than the Government is assuming, putting further pressure on super funds to liquidate assets.

Warwick McKibbin is widely-regarded for creating the leading economic model on how the world operates. His paper on seven scenarios includes worse forecasts than the market is considering.

Where do we find optimism with more deaths every day? Christopher Joye has produced a deep analysis of the global spread of the pandemic and his models suggest infections will start declining in the US and Australia in the second half of April. That's only a month away if containment remains strict. We need to differentiate between long delays in producing a vaccine versus early treatments. Joye is particularly optimistic about an anti-viral drug called hydroxychloroquine and its availability as a treatment soon.

Rob Arnott is a leading academic and fund manager in the US, and in my interview, he is highly critical that the US and Australia have not learned the virus lessons from South Korea and Japan. Despite the crushing of the economy, he looks longer term and "this too shall pass".

In December 2019, I wrote an article, 'Sorry, there's no real place to hide", which included this:

"Many of the conservative investors who have pumped billions into the new LITs and fixed interest ETFs are the same investors who cannot tolerate share market risk. They have traded one type of risk for another, albeit with less downside and less upside potential. But critically, downside potential there is, and it’s not short-term capital preservation."

The recent collapse of Listed Investment Trust prices to well below their net asset values, in some cases a 50% fall from their recent issue prices, has seen a destruction of wealth of $1 billion on eight transactions. As soon as Josh Frydenberg is not distracted by a greater calling, he needs to get back to banning selling fees on listed vehicles. But do the LITs now offer value?

Gold has come into the investment spotlight recently as a potential bulwark in troubling times, and Jordan Eliseo highlights an important ratio that can show the market mood.

Andrew Baker is well known in Australian wealth management. He now works in the UK and took his family to rural France for a holiday. Caught in a lockdown, he sent this warning.

Jonathan Rochford returns with his monthly review of stories the local media missed, including the unusual, controversial and plain quirky.

Back on gold, this week's Sponsor White Paper from The Perth Mint makes the case for an allocation to the metal in a diversified portfolio.


Graham Hand, Managing Editor

For a PDF version of this week’s newsletter articles, click here.



Most viewed in recent weeks

11 lessons from my lousy $50K profit on Afterpay

Afterpay listed at $1 in 2016 and traded recently at $70. How should an investor treat a small holding in a 70-bagger when each new level defies the experts? Should true believers let the profits run?

How much bigger can the virus bubble get?

Stocks have rallied hard creating a virus bubble, but will this run for years or collapse in a matter of months? The market is giving a second chance to leave so head for the exit before there's a rush.

Share trading is the new addiction

The ability to buy and sell cheaply and quickly in small parcels is both the biggest drawback and benefit of shares. But it encourages people who should not go near the market to use it as a casino.

What is happening with SMSFs? Part 1

Taking a realistic view of the median ‘operating expense’ of an SMSF shows they cost less to run than previously claimed. Look at this granular breakdown and see how the costs of running your SMSF compare.

New ways for listed funds to fix their price discounts

Running a fund should not become a gravy train for boards and investment managers. It is time to address the persistent discounts to NTA on LICs, and there is one especially exciting new structure.

Howard Marks' anatomy of an unexpected rally

Markets can swing quickly from optimism to pessimism, and while there are more positives now than in the bleak early days in March, the market is ignoring many negatives. Risk is not rewarded at these levels.

Latest Updates

Investment strategies

11 lessons from my lousy $50K profit on Afterpay

Afterpay listed at $1 in 2016 and traded recently at $70. How should an investor treat a small holding in a 70-bagger when each new level defies the experts? Should true believers let the profits run?


How did shares perform in FY20 and where to from here?

Compared with most years in the last decade, FY20 performed poorly due to the virus, and now dividends are falling. There are three things to watch this year as support policies are wound back.


Which companies will do well in the turmoil of 2020?

While the shutting of Australia’s borders to international travellers and quarantine measures is damaging to certain sectors of the economy, it is not uniformly negative for all companies.

Investment strategies

Six types of big data are unlocking real insights

Data science is increasingly embedded into the research process of investment teams with the resources to exploit new technologies. The way the data is integrated and interpreted is crucial.


Will value stocks benefit from the market's inflection point?

As the world gradually emerges from the aftermath of COVID-19, many are questioning if now is value’s time to shine? How can value stocks deliver outperformance in today’s environment?

Fixed interest

Less than 1% for 100 years: watch the price risk on long bonds

Do you think investors can only lose heavily on bonds if the credit defaults? When bondholders accept 0.88% for 100 years, there is great potential for serious pain somewhere along the journey.


Five industries profoundly changed by COVID-19

Even when the virus is finally contained, the business landscape will look very different. A critical issue is the ability of consumers to find product substitutes. Many people like what they find.

Exchange traded products

Wirecard shows not all ethical ETFs pass the smell test

The strictness of screening processes can vary between ethical ETFs, and many rely on indices without additional oversight. This can result in stock inclusions that may not pass the ethical ‘smell test’.



© 2020 Morningstar, Inc. All rights reserved.

The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use.
Any general advice or class service prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, has been prepared by without reference to your objectives, financial situation or needs. Refer to our Financial Services Guide (FSG) for more information. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.